DECISION Trial: Digoxin Withdrawal Linked to Clinical Deterioration in Heart Failure
Key Highlights
Medicine · Cardiology
The DECISION trial’s prespecified withdrawal analysis provides high-grade evidence that discontinuing long-term low-dose digoxin in patients with heart failure and reduced or mildly reduced ejection fraction leads to significant clinical deterioration. Researchers found that the incidence rate of cardiovascular death or worsening heart failure events surged to 42.8 events per 100 patient-years after digoxin withdrawal, compared to 5.9 events in the placebo withdrawal arm (RR 7.37, 95% CI 1.56–34.88; P=0.012). For a medical student focused on evidence-based acute care and patient outcomes, this finding is directly actionable: it underscores the critical importance of cautious medication reconciliation and highlights that even an older, guideline-recommended therapy like digoxin can have profound withdrawal risks that must be considered in clinical decision-making.
Novelty: 78%
Rigor: 92%
Significance: 88%
Validity: 90%
Clarity: 85%
Update Your Briefing Preferences
Stay curious. Stay informed —
Science Briefing
Your briefing is personalized based on your selected fields, keywords, and research interests.
